Amina Merzoug

Amina Merzoug

Auto-generated profile, based on publicly available information

Amina Merzoug

Laboratory of Applied Biochemistry, Department of Biochemistry and Cellular and Molecular Biology, Faculty of Natural and Life Sciences, Mentouri Brothers University, Constantine 1, Algeria

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2017 in Molecular Informatics
Verified
Journal Article
Closed access
PDF file
AMAmina Merzoug
Amina Merzoug
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
HBHanane Boucherit
Hanane Boucherit
SEZER OKAYSEZER OKAY
SEZER OKAY

1 March 2021 in Current Issues in Pharmacy and Medical Sciences
Verified
Journal Article
Open access
AMAmina Merzoug
Amina Merzoug
HBHanane Boucherit
Hanane Boucherit
RKRima Khaled
Rima Khaled
ACAmel Chefiri
Amel Chefiri
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
While Alzheimer disease is the most common form of dementia, acetylcholinesterase is an interesting therapeutic target for the development of new anti-Alzheimer’s disease drugs. In order to discover potential compounds inhibiting this protein target, a molecular docking study of a similar collection of 1-[[2,4-bis[(E)hydroxyiminomethyl] pyridin-1-ium-1-yl]methoxymethyl] pyridin-1-ium-4-carboxamide (HLO) inhibitor from ZINC database using FlexX program was realized. Before performing the molecular docking, FlexX was validated by Root mean square deviation test to determine the reproducibility of the docking program. The strategy undertaken in this study permitted us to propose products 4-[[2-[(Z)-N’-hydroxycarbamimidoyl]-4-pyridyl]methylamino] benzamide and N-[(E)-[1-(4-nitrophenyl)pyrrol-2-yl]methylene amino]isonicotinamide as potential new inhibitors of humane acetylcholinesterase. The two proposed products may act as strong anti-Alzheimer leads compounds.

3 September 2020 in Current Computer-Aided Drug Design
Verified
Journal Article
Closed access
PDF file
HBHanane Boucherit
Hanane Boucherit
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
AMAmina Merzoug
Amina Merzoug
jean Michel Bruneljean Michel Brunel
jean Michel Brunel
Background: The great emergence of multi-resistant bacterial strains and the low renewal of antibiotics molecules are leading human and veterinary medicine to certain therapeutic impasses. Therefore, there is an urgent need to find new therapeutic alternatives including new molecules in the current treatments of infectious diseases. Methionine aminopeptidase (MetAP) is a promising target for developing new antibiotics because it is essential for bacterial survival. Objective: To screen for potential MetAP inhibitors by in silico virtual screening of the ZINC database and evaluate the best potential lead molecules by in vitro studies. Methods: We have considered 200,000 compounds from the ZINC database for virtual screening with FlexX software to identify potential inhibitors against bacterial MetAP. Nine chemical compounds of the top hits predicted were purchased and evaluated in vitro. The antimicrobial activity of each inhibitor of MetAP was tested by the disc-diffusion assay against one Gram-positive (Staphylococcus aureus) and two Gram-negative (Escherichia coli & Pseudomonas aeruginosa) bacteria. Among the studied compounds, compounds ZINC04785369 and ZINC03307916 showed promising antibacterial activity. To further characterize their efficacy, the minimum inhibitory concentration was determined for each compound by the microdilution method which showed significant results. Results: These results suggest compounds ZINC04785369 and ZINC03307916 as promising molecules for developing MetAP inhibitors. Conclusion: Furthermore, they could therefore serve as lead molecules for further chemical modifications to obtain clinically useful antibacterial agents.

19 October 2019 in Current Enzyme Inhibition
Verified
Journal Article
Open access
PDF file
AMAmina Merzoug
Amina Merzoug
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
HBHanane Boucherit
Hanane Boucherit
SHSawsen Hadef
Sawsen Hadef
Aim and Objective: The antibacterial therapy resistance poses an urgent threat to the public’s health. Peptide deformylase is a favorable target to identify new antibiotics with novel mechanism of action. Materials and Methods: In order to discovery new potent inhibitors of this enzyme, the virtual screening method of Zinc database using the binding site of Enterococcus faecalis peptide deformylase combined with microbiological assay were realized. Results: The strategy undertaken in this study allowed us to identify new products with growth inhibition activity. The best result was obtained for the chemicals 4-(1,3-dioxo-1Hbenzo[de]isoquinolin- 2(3H)-yl)-N-hydroxybutanamide and N-hydroxy-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl) acetamide, they showed good affinities and great antibacterial activities compared to the other studied products. Conclusion: The two most promising compounds can serve as potential antibacterial agents.

1 January 2013 in Trends in Bioinformatics
Verified
Journal Article
Closed access
AMAmina Merzoug
Amina Merzoug
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
KHKhadidja Soulef Hio
Khadidja Soulef Hio
HBHanane Boucherit
Hanane Boucherit
STSoumia Teniou
Soumia Teniou
The drug resistance is a serious problem in malaria. So, the present strategy for new drug development is directed towards identifying essential enzyme systems in the parasite and developing potent molecules to inhibit them. A peptide deformylase (PDF) gene was identified in the Plasmodium falciparum genome and was suggested as a new target for antimalarial therapy. The aim of this study was to analyze the interactions between the PDF of Plasmodium falciparum (pfPDF) and the actinonin, naturally occurring PDF inhibitors to explore their binding modes and to make tests of modelling with a view to identify novel and more efficient antimalarial drugs. The binding modes have been studied using molecular docking software FlexX. The study of the modelling realized on the actinonin shows that the binding energy can be decreased in a significant way by a judicious choice of fragments to be substituted. Replacement of the hydroxymethyl group of the pfPDF inhibitor with an hydroxyl and the Pentyl group by a cyclopentyl-ethyl enhances the binding energy from-24.73 to -35.11 kJ mol-1. The biological potentialities of these proposed compounds were checked by their pharmacokinetic properties and they showed no toxicity.

1 January 2017 in Cancer Reports and Reviews
Verified
Journal Article
Open access
HBHanane Boucherit
Hanane Boucherit
NZNousseiba Zouaghi
Nousseiba Zouaghi
ZSZiani Sara
Ziani Sara
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
AMAmina Merzoug
Amina Merzoug
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.